- Home
- STI vs FBIO Comparison
STI vs FBIO Comparison
Compare STI & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STI
- FBIO
- Stock Information
- Founded
- STI 2014
- FBIO 2006
- Country
- STI United States
- FBIO United States
- Employees
- STI N/A
- FBIO N/A
- Industry
- STI
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- STI
- FBIO Health Care
- Exchange
- STI NYSE
- FBIO Nasdaq
- Market Cap
- STI 46.6M
- FBIO 39.4M
- IPO Year
- STI N/A
- FBIO N/A
- Fundamental
- Price
- STI $0.40
- FBIO $1.85
- Analyst Decision
- STI
- FBIO Strong Buy
- Analyst Count
- STI 0
- FBIO 3
- Target Price
- STI N/A
- FBIO $18.00
- AVG Volume (30 Days)
- STI 2.2M
- FBIO 691.0K
- Earning Date
- STI 11-19-2024
- FBIO 11-14-2024
- Dividend Yield
- STI N/A
- FBIO N/A
- EPS Growth
- STI N/A
- FBIO N/A
- EPS
- STI N/A
- FBIO N/A
- Revenue
- STI $5,329.00
- FBIO $81,501,000.00
- Revenue This Year
- STI N/A
- FBIO N/A
- Revenue Next Year
- STI N/A
- FBIO $134.70
- P/E Ratio
- STI N/A
- FBIO N/A
- Revenue Growth
- STI 32.73
- FBIO 31.51
- 52 Week Low
- STI $0.27
- FBIO $1.36
- 52 Week High
- STI $11.89
- FBIO $4.43
- Technical
- Relative Strength Index (RSI)
- STI 48.35
- FBIO 49.60
- Support Level
- STI $0.40
- FBIO $1.78
- Resistance Level
- STI $0.45
- FBIO $2.27
- Average True Range (ATR)
- STI 0.04
- FBIO 0.17
- MACD
- STI -0.00
- FBIO -0.03
- Stochastic Oscillator
- STI 18.71
- FBIO 21.43
About STI SOLIDION TECHNOLOGY INC
Solidion Technology Inc is engaged in researching, developing and manufacturing battery materials and components, as well as the development and production of next-generation batteries for energy storage systems and electric vehicles for ground, air, and sea transportation. It is recognized as a global IP leader in both the high-capacity anode and the high-energy solid-state battery.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.